Literature DB >> 11046017

A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.

A Hameg1, I Apostolou, M Leite-De-Moraes, J M Gombert, C Garcia, Y Koezuka, J F Bach, A Herbelin.   

Abstract

In the present report, we characterize a novel T cell subset that shares with the NKT cell lineage both CD1d-restriction and high reactivity in vivo and in vitro to the alpha-galactosylceramide (alpha-GalCer) glycolipid. These cells preferentially use the canonical Valpha14-Jalpha281 TCR-alpha-chain and Vbeta8 TCR-beta segments, and are stimulated by alpha-GalCer in a CD1d-dependent fashion. However, in contrast to classical NKT cells, they lack the NK1.1 marker and express high surface levels of CD1d molecules. In addition, this NK1.1(-) CD1d(high) T subset, further referred to as CD1d(high) NKT cells, can be distinguished by its unique functional features. Although NK1.1(+) NKT cells require exogenous CD1d-presenting cells to make them responsive to alpha-GalCer, CD1d(high) NKT cells can engage their own surface CD1d in an autocrine and/or paracrine manner. Furthermore, in response to alpha-GalCer, CD1d(high) NKT cells produce high amounts of IL-4 and moderate amounts of IFN-gamma, a cytokine profile more consistent with a Th2-like phenotype rather than the Th0-like phenotype typical of NK1.1(+) NKT cells. Our work reveals a far greater level of complexity within the NKT cell population than previously recognized and provides the first evidence for T cells that can be activated upon TCR ligation by CD1d-restricted recognition of their ligand in the absence of conventional APCs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046017     DOI: 10.4049/jimmunol.165.9.4917

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Rapid development of a gamma interferon-secreting glycolipid/CD1d-specific Valpha14+ NK1.1- T-cell subset after bacterial infection.

Authors:  Masashi Emoto; Izumi Yoshizawa; Yoshiko Emoto; Mamiko Miamoto; Robert Hurwitz; Stefan H E Kaufmann
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

2.  Type I interferon contributes to noncanonical inflammasome activation, mediates immunopathology, and impairs protective immunity during fatal infection with lipopolysaccharide-negative ehrlichiae.

Authors:  Qin Yang; Heather L Stevenson; Melanie J Scott; Nahed Ismail
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

3.  Freshly isolated Valpha24+ CD4+ invariant natural killer T cells activated by alpha-galactosylceramide-pulsed B cells promote both IgG and IgE production.

Authors:  A Rossignol; A Barra; A Herbelin; J-L Preud'homme; J-M Gombert
Journal:  Clin Exp Immunol       Date:  2007-03-15       Impact factor: 4.330

4.  Invariant NKT Cell Lines Derived from the NOD·H2 Mouse Enhance Autoimmune Thyroiditis.

Authors:  Rajni B Sharma; Xiaoguang Fan; Patrizio Caturegli; Noel R Rose; C Lynne Burek
Journal:  J Thyroid Res       Date:  2011-04-10

5.  A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage.

Authors:  Daniel G Pellicci; Kirsten J L Hammond; Adam P Uldrich; Alan G Baxter; Mark J Smyth; Dale I Godfrey
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

Review 6.  B cells interactions in lipid immune responses: implications in atherosclerotic disease.

Authors:  Laura C Echeverri Tirado; Lina M Yassin
Journal:  Lipids Health Dis       Date:  2017-02-06       Impact factor: 3.876

7.  IL-15 availability conditions homeostasis of peripheral natural killer T cells.

Authors:  Thomas Ranson; Christian A J Vosshenrich; Erwan Corcuff; Odile Richard; Veronique Laloux; Agnès Lehuen; James P Di Santo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-21       Impact factor: 11.205

Review 8.  Intracellular bacterial infection and invariant NKT cells.

Authors:  Masashi Emoto; Yoshiko Emoto
Journal:  Yonsei Med J       Date:  2009-02-24       Impact factor: 2.759

9.  Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome.

Authors:  D Kudo; M Toyama; T Aoyagi; Y Akahori; H Yamamoto; K Ishii; E Kanno; R Maruyama; M Kaku; S Kushimoto; K Kawakami
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

10.  Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer.

Authors:  Atsushi Horinaka; Daiju Sakurai; Fumie Ihara; Yuji Makita; Naoki Kunii; Shinichiro Motohashi; Toshinori Nakayama; Yoshitaka Okamoto
Journal:  Cancer Sci       Date:  2016-02-13       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.